Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy

Shiro Watanabe,Tetsuya Inoue,Shozo Okamoto,Keiichi Magota,Ayumi Takayanagi,Jun Sakakibara-Konishi,Norio Katoh,Kenji Hirata,Osamu Manabe,Takuya Toyonaga,Yuji Kuge,Hiroki Shirato,Nagara Tamaki,Tohru Shiga

Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy

2019

Shiro Watanabe
Tetsuya Inoue
Shozo Okamoto
Keiichi Magota
Ayumi Takayanagi
Jun Sakakibara-Konishi
Norio Katoh
Kenji Hirata
Osamu Manabe
Takuya Toyonaga
Yuji Kuge
Hiroki Shirato
Nagara Tamaki
Tohru Shiga

Background We investigated the prognostic predictive value of the combination of fluorodeoxyglucose (FDG)- and fluoromisonidazole (FMISO)-PET in patients with non-small cell lung carcinoma (NSCLC) treated with stereotactic body radiation therapy (SBRT).

Keywords:

stereotactic radiotherapy
FMISO
Cardiac imaging
Carcinoma
Fluorodeoxyglucose
Radiology
Lung
stereotactic body radiation therapy
Medicine
treatment strategy
Standardized uptake value
Nuclear medicine
fmiso pet
Univariate analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations